Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.

Chirality - 1 Jun 2005

Miura Masatomo, Tada Hitoshi, Yasui-Furukori Norio, Uno Tsukasa, Sugawara Kazunobu, Tateishi Tomonori, Suzuki Toshio

Abstract excerpt

The aim of this study was to examine the effect of clarithromycin, a CYP3A4 inhibitor, on the enantioselective disposition of lansoprazole among three different CYP2C19 genotype groups in healthy Japanese subjects. These subjects included 6 each of homozygous extensive metabolizers (homEMs), heterozygous extensive metabolizers (hetEMs), and poor metabolizers (PMs). In the EMs of CYP2C19, clarithromycin markedly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Clarithromycin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Cytochrome P-450 Enzyme Inhibitors

Share to Lansoprazole

Share to Omeprazole

Share to Proton Pump Inhibitors

Share to Stereoisomerism

Source

Identifiers

PMID: 15856433
DOI: 10.1002/chir.20159

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.PMID 15856433Read ↗

Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.Semantic proximity Read ↗

Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.Semantic proximity Read ↗

Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes.Semantic proximity Read ↗

Enantioselective disposition of lansoprazole and rabeprazole in human plasma.Semantic proximity Read ↗

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.Semantic proximity Read ↗

Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.Semantic proximity Read ↗

The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.Semantic proximity Read ↗

Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.Semantic proximity Read ↗

Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.Semantic proximity Read ↗

Correlation between R/S enantiomer ratio of lansoprazole and CYP2C19 activity after single oral and enteral administration.Semantic proximity Read ↗

Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.